Artiva Biotherapeutics, Inc. (ARTV) Stock Forecast & Price Target

Compare

432 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ARTV Analyst Ratings

Strong Buy

5 Buy

0 Hold

0 Sell

Based on 5 analysts giving stock ratings to

Artiva

Biotherapeutics, Inc.

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ARTV Stock 12 Month Forecast

Average Price Target

$16.50

▲(262.64% Upside)

Based on 5 Wall Street analysts offering 12 month price targets for Artiva Biotherapeutics, Inc. in the last 3 months. The average price target is $16.50 with a high forecast of $23.00 and a low forecast of $10.00. The average price target represents a 262.64% change from the last price of $4.55.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","6":"$6","12":"$12","18":"$18","24":"$24"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":23,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$23.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$16.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,6,12,18,24],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.47,4.972307692307693,6.474615384615385,7.976923076923077,9.47923076923077,10.981538461538461,12.483846153846155,13.986153846153847,15.48846153846154,16.99076923076923,18.493076923076924,19.995384615384616,21.497692307692308,{"y":23,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.47,4.472307692307693,5.474615384615385,6.476923076923077,7.479230769230769,8.481538461538461,9.483846153846155,10.486153846153847,11.48846153846154,12.490769230769232,13.493076923076924,14.495384615384616,15.49769230769231,{"y":16.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.47,3.9723076923076923,4.474615384615385,4.976923076923077,5.479230769230769,5.981538461538461,6.483846153846153,6.9861538461538455,7.488461538461538,7.99076923076923,8.493076923076922,8.995384615384614,9.497692307692308,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":10.72,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.75,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.08,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.15,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.37,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.94,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.53,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.83,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.09,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.92,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.17,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.47,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$23.00

Average Price Target$16.50

Lowest Price Target$10.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Tyler Van Buren

TD Cowen

―

Buy

―

Reiterated

11/12/25

Promising Developments in Artiva Biotherapeutics' AlloNK Therapy for Autoimmune Diseases

Emily Bodnar

H.C. Wainwright

$12→$15

Buy

229.67%

Upside

Reiterated

11/12/25

Buy Rating for Artiva Biotherapeutics Based on Promising AlloNK Combination Therapy Results

Gil Blum

Needham

$18

Buy

295.60%

Upside

Reiterated

11/12/25

Buy Rating for Artiva Biotherapeutics, Inc. Based on Promising Clinical Results and Competitive Edge6:13 PM 2025 ESTIMATE CHANGE Biotechnology Artiva Biotherapeutics (ARTV) RATING BUY PRICE TARGET $18.00 PREV CLOSE $3.59 52-WEEK RANGE $1.47 - $13.85 Initial AID Results are as Good as Can be Artiva presented early safety and translational results from 32 autoimmune patients dosed with alloNK to date. Early results demonstrate remarkable safety with no reports of either CRS or ICANS and only minimal reports of infections (a single grade 3 event) despite use of Flu/Cy conditioning. Notably, the majority of patients were dosed in the community setting. B-cell aplasia data disclosed, with ~3 months of suppression, shows a profile as good as or better than what's been presented for other modalities such as CAR-Ts or TCEs.

Martin Fan

Wedbush

$23

Buy

405.49%

Upside

Reiterated

11/12/25

Joshua Schimmer

Cantor Fitzgerald

$10

Buy

119.78%

Upside

Reiterated

10/16/25

Analysts Offer Insights on Healthcare Companies: Taysha Gene Therapies (NASDAQ: TSHA), Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) and Perspective Therapeutics (NYSE MKT: CATX)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Tyler Van Buren

TD Cowen

―

Buy

―

Reiterated

11/12/25

Promising Developments in Artiva Biotherapeutics' AlloNK Therapy for Autoimmune Diseases

Emily Bodnar

H.C. Wainwright

$12→$15

Buy

229.67%

Upside

Reiterated

11/12/25

Buy Rating for Artiva Biotherapeutics Based on Promising AlloNK Combination Therapy Results

Gil Blum

Needham

$18

Buy

295.60%

Upside

Reiterated

11/12/25

Martin Fan

Wedbush

$23

Buy

405.49%

Upside

Reiterated

11/12/25

Joshua Schimmer

Cantor Fitzgerald

$10

Buy

119.78%

Upside

Reiterated

10/16/25

Analysts Offer Insights on Healthcare Companies: Taysha Gene Therapies (NASDAQ: TSHA), Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) and Perspective Therapeutics (NYSE MKT: CATX)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Artiva Biotherapeutics, Inc.

1 Month

xxx

Success Rate

2/7 ratings generated profit

Average Return

-1.80%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 28.57% of your transactions generating a profit, with an average return of -1.80% per trade.

3 Months

xxx

Success Rate

5/7 ratings generated profit

Average Return

-0.14%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 71.43% of your transactions generating a profit, with an average return of -0.14% per trade.

1 Year

Gil BlumNeedham

Success Rate

5/8 ratings generated profit

Average Return

+21.86%

reiterated a buy rating last month

Copying Gil Blum's trades and holding each position for 1 Year would result in 62.50% of your transactions generating a profit, with an average return of +21.86% per trade.

2 Years

xxx

Success Rate

6/8 ratings generated profit

Average Return

+73.32%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 75.00% of your transactions generating a profit, with an average return of +73.32% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ARTV Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ARTV has received 8 Buy Ratings, 10 Hold Ratings, and 0 Sell Ratings. ARTV average Analyst price target in the past 3 months is 16.50.

Each month's total comprises the sum of three months' worth of ratings.

ARTV Financial Forecast

ARTV Earnings Forecast

Next quarter’s earnings estimate for ARTV is -$0.84 with a range of -$0.91 to -$0.72. The previous quarter’s EPS was -$0.88. ARTV beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year ARTV has Performed in-line its overall industry.

No data currently available

ARTV Sales Forecast

Next quarter’s sales forecast for ARTV is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. ARTV beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year ARTV has Performed in-line its overall industry.

ARTV Stock Forecast FAQ

What is ARTV’s average 12-month price target, according to analysts?

Based on analyst ratings, Artiva Biotherapeutics, Inc.’s 12-month average price target is 16.50.

What is ARTV’s upside potential, based on the analysts’ average price target?

Artiva Biotherapeutics, Inc. has 262.64% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ARTV a Buy, Sell or Hold?

Artiva Biotherapeutics, Inc. has a consensus rating of Strong Buy which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.

What is Artiva Biotherapeutics, Inc.’s price target?

The average price target for Artiva Biotherapeutics, Inc. is 16.50. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $23.00 ,the lowest forecast is $10.00. The average price target represents 262.64% Increase from the current price of $4.55.

What do analysts say about Artiva Biotherapeutics, Inc.?

Artiva Biotherapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.

How can I buy shares of ARTV?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Artiva Biotherapeutics, Inc. (ARTV) Stock Forecast & Price Target

ARTV Analyst Ratings

ARTV Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Artiva Biotherapeutics, Inc.

ARTV Analyst Recommendation Trends

ARTV Financial Forecast

ARTV Earnings Forecast

ARTV Sales Forecast

ARTV Stock Forecast FAQ

Detailed List of Analyst Forecasts